Skip to main content
Premium Trial:

Request an Annual Quote

Genzyme Enters into Genomics Agreements With Ontogeny, Hexagen


CAMBRIDGE, Mass.--Develop mental biology-based biotech Ontogeny and Genzyme Molecu lar Oncology, developer of gene-based approaches to cancer diagnosis and therapy, announced a collaborative agreement under which Genzyme will produce its proprietary Sage libraries to enable Ontogeny to analyze differential gene expression. Sage is a high-efficiency, high-throughput method of simultaneously detecting and measuring the expression levels of virtually all genes expressed in a cell at a given time.

Using RNA supplied by Ontogeny, Genzyme will produce RNA Sage libraries that Ontogeny will incorporate into its developmental biology discovery system. Identified genes will be processed through Ontogeny's screening system to validate leads and targets. Financial terms were not disclosed.

In another deal, Genzyme agreed to provide genetic research firm Hexagen of Cambridge, UK, with Sage technology for use in Hexagen's disease discovery programs. Hexagen will pay Genzyme an undisclosed service fee and will retain exclusive rights to information that results from the collaboration.

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.